Table 4 Seropositivity rates and GMTs for anti-CS antibodies from Months 0 to 20 (ATP Cohort for Immunogenicity)
Group | Timing | N | Seropositive | GMT (EU/mL) | Â | Â | |||
|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | n | % | 95% CI | Â | value | 95% CI | Â |
RTS,S/AS02D | SCREENING | 141 | 33 | 23.4 | 16.7 | 31.3 | 0.3 | 0.3 | 0.4 |
| Â | Post Dose 2 (Month 2) | 151 | 149 | 98.7 | 95.3 | 99.8 | 28.9 | 22.4 | 37.3 |
| Â | Post Dose 3 (Month 3) | 143 | 141 | 98.6 | 95.0 | 99.8 | 69.5 | 53.9 | 89.6 |
| Â | Post Dose 3 (Month 9) | 143 | 127 | 88.8 | 82.5 | 93.5 | 6.2 | 4.6 | 8.3 |
| Â | Post Dose 3 (Month 14) | 142 | 107 | 75.4 | 67.4 | 82.2 | 3.0 | 2.2 | 4.0 |
| Â | Post Dose 3 (Month 20) | 131 | 94 | 71.8 | 63.2 | 79.3 | 1.9 | 1.4 | 2.6 |
Hepatitis B | SCREENING | 152 | 39 | 25.7 | 18.9 | 33.4 | 0.4 | 0.3 | 0.4 |
vaccine | Post Dose 2 (Month 2) | 156 | 10 | 6.4 | 3.1 | 11.5 | 0.3 | 0.3 | 0.3 |
| Â | Post Dose 3 (Month 3) | 144 | 2 | 1.4 | 0.2 | 4.9 | 0.3 | 0.2 | 0.3 |
| Â | Post Dose 3 (Month 9) | 147 | 0 | 0.0 | 0.0 | 2.5 | 0.3 | 0.3 | 0.3 |
| Â | Post Dose 3 (Month 14) | 139 | 2 | 1.4 | 0.2 | 5.1 | 0.3 | 0.2 | 0.3 |
| Â | Post Dose 3 (Month 20) | 132 | 5 | 3.8 | 1.2 | 8.6 | 0.3 | 0.3 | 0.3 |